From: Health-related quality of life in Marfan syndrome: a 10-year follow-up
Females, n (%) | 34 (72.3) |
---|---|
Age, mean (SD) | 49.9 (11.7) |
FBN1 mutation (%) | 45 (95.7) |
Body mass index, mean (SD) | 25.3 (5.7) |
β-Adrenergic blocking agents or other antihypertensive medication, n (%) | 35 (74.5) |
Ascending aortic dilatationa at follow-up, n (%) | 43 (91.5) |
Aortic surgery during life, n (%) | 30 (63.8) |
New cardiovascular pathology during follow-up, n (%) | 21 (44.7) |
New non-cardiovascular pathology during follow-up, n (%) | 14 (29.8) |